Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
9.07
+0.22 (2.49%)
At close: Jul 17, 2025, 4:00 PM
9.03
-0.04 (-0.44%)
After-hours: Jul 17, 2025, 7:59 PM EDT

Aurinia Pharmaceuticals Stock Forecast

Stock Price Forecast

The 2 analysts that cover Aurinia Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $11.5, which forecasts a 26.79% increase in the stock price over the next year. The lowest target is $10 and the highest is $13.

Price Target: $11.5 (+26.79%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$10$11.5$13$13
Change+10.25%+26.79%+43.33%+43.33%
* Price targets were last updated on Sep 16, 2024.

Analyst Ratings

The average analyst rating for Aurinia Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingFeb '25Mar '25Apr '25May '25Jun '25Jul '25
Strong Buy111111
Buy222221
Hold000000
Sell000000
Strong Sell000000
Total333332

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterates
$10
BuyReiterates$10+10.25%Sep 16, 2024
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterates
$10
BuyReiterates$10+10.25%Sep 9, 2024
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$13
Strong BuyReiterates$13+43.33%Sep 6, 2024
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$13
Strong BuyReiterates$13+43.33%Mar 1, 2024
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Maintains
$12$10
BuyMaintains$12$10+10.25%Feb 23, 2024
More Analyst Ratings

Financial Forecast

Revenue This Year
263.69M
from 235.13M
Increased by 12.15%
Revenue Next Year
312.06M
from 263.69M
Increased by 18.34%
EPS This Year
0.60
from 0.04
Increased by 1,394.30%
EPS Next Year
0.77
from 0.60
Increased by 29.35%
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
50.12M45.61M134.03M175.51M235.13M263.69M312.06M364.60M
Revenue Growth
15,660.38%-9.01%193.89%30.95%33.97%12.15%18.34%16.84%
EPS
-0.87-1.40-0.76-0.540.040.600.771.05
EPS Growth
-----1,394.30%29.35%35.55%
Forward PE
-----15.1711.738.65
No. Analysts
-----776
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20252026202720282029
High273.0M373.6M469.0M
Avg263.7M312.1M364.6M
Low251.1M284.2M313.6M

Revenue Growth

Revenue Growth20252026202720282029
High
16.1%
41.7%
50.3%
Avg
12.1%
18.3%
16.8%
Low
6.8%
7.8%
0.5%

EPS Forecast

EPS20252026202720282029
High0.801.251.63
Avg0.600.771.05
Low0.440.530.78

EPS Growth

EPS Growth20252026202720282029
High
1,895.0%
109.0%
110.5%
Avg
1,394.3%
29.4%
35.6%
Low
1,002.5%
-11.5%
1.4%
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.